CN1069193C - 含三环化合物的软膏的制备方法 - Google Patents
含三环化合物的软膏的制备方法 Download PDFInfo
- Publication number
- CN1069193C CN1069193C CN91108796A CN91108796A CN1069193C CN 1069193 C CN1069193 C CN 1069193C CN 91108796 A CN91108796 A CN 91108796A CN 91108796 A CN91108796 A CN 91108796A CN 1069193 C CN1069193 C CN 1069193C
- Authority
- CN
- China
- Prior art keywords
- hydroxyl
- hydrogen atom
- ointment
- alkyl
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 64
- 150000001875 compounds Chemical class 0.000 title claims abstract description 39
- 239000003883 ointment base Substances 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 4
- -1 alkyl glycol Chemical compound 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 34
- 238000003756 stirring Methods 0.000 claims description 32
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 238000010438 heat treatment Methods 0.000 claims description 25
- 238000010521 absorption reaction Methods 0.000 claims description 23
- 239000001301 oxygen Substances 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 239000003623 enhancer Substances 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- 150000001721 carbon Chemical group 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 125000005456 glyceride group Chemical group 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- ACIAHEMYLLBZOI-ZZXKWVIFSA-N Unsaturated alcohol Chemical compound CC\C(CO)=C/C ACIAHEMYLLBZOI-ZZXKWVIFSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 125000003700 epoxy group Chemical group 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 235000019940 salatrim Nutrition 0.000 claims description 2
- 125000001118 alkylidene group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 230000002745 absorbent Effects 0.000 claims 1
- 239000002250 absorbent Substances 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000003381 solubilizing effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 description 62
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 22
- 239000003871 white petrolatum Substances 0.000 description 22
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 20
- 229940057995 liquid paraffin Drugs 0.000 description 19
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical group CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 19
- 239000007765 cera alba Substances 0.000 description 17
- 239000002585 base Substances 0.000 description 16
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 14
- 229940031578 diisopropyl adipate Drugs 0.000 description 14
- 239000012188 paraffin wax Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229940055577 oleyl alcohol Drugs 0.000 description 6
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 6
- 238000003825 pressing Methods 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 4
- 125000001589 carboacyl group Chemical group 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 4
- 239000004200 microcrystalline wax Substances 0.000 description 4
- 235000019808 microcrystalline wax Nutrition 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 238000006884 silylation reaction Methods 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 3
- 241000723346 Cinnamomum camphora Species 0.000 description 3
- 206010048768 Dermatosis Diseases 0.000 description 3
- ONKUXPIBXRRIDU-UHFFFAOYSA-N Diethyl decanedioate Chemical compound CCOC(=O)CCCCCCCCC(=O)OCC ONKUXPIBXRRIDU-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 229960000846 camphor Drugs 0.000 description 3
- 229930008380 camphor Natural products 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- GUSTUIJJPMXTTI-UHFFFAOYSA-N 1-dodecylazepane Chemical compound CCCCCCCCCCCCN1CCCCCC1 GUSTUIJJPMXTTI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- MMKRHZKQPFCLLS-UHFFFAOYSA-N ethyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OCC MMKRHZKQPFCLLS-UHFFFAOYSA-N 0.000 description 2
- 125000001924 fatty-acyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- FOWDZVNRQHPXDO-UHFFFAOYSA-N propyl hydrogen carbonate Chemical compound CCCOC(O)=O FOWDZVNRQHPXDO-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- OQQOAWVKVDAJOI-UHFFFAOYSA-N (2-dodecanoyloxy-3-hydroxypropyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCC OQQOAWVKVDAJOI-UHFFFAOYSA-N 0.000 description 1
- JSLZUBLGGPEVQN-DIPNUNPCSA-N (2r)-4-methyl-2-propan-2-yl-2-[2-[4-[4-[2-(3,4,5-trimethoxyphenyl)ethyl]piperazin-1-yl]butoxy]phenyl]-1,4-benzothiazin-3-one Chemical compound COC1=C(OC)C(OC)=CC(CCN2CCN(CCCCOC=3C(=CC=CC=3)[C@@]3(C(N(C)C4=CC=CC=C4S3)=O)C(C)C)CC2)=C1 JSLZUBLGGPEVQN-DIPNUNPCSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- AFSHUZFNMVJNKX-LLWMBOQKSA-N 1,2-dioleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC\C=C/CCCCCCCC AFSHUZFNMVJNKX-LLWMBOQKSA-N 0.000 description 1
- 125000004806 1-methylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- UDSFAEKRVUSQDD-UHFFFAOYSA-N Dimethyl adipate Chemical compound COC(=O)CCCCC(=O)OC UDSFAEKRVUSQDD-UHFFFAOYSA-N 0.000 description 1
- 206010053177 Epidermolysis Diseases 0.000 description 1
- 206010015152 Erythema Ab Igne Diseases 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024380 Leukoderma Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 206010029491 Nodular vasculitis Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940031955 anhydrous lanolin Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Substances ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000002592 cumenyl group Chemical group C1(=C(C=CC=C1)*)C(C)C 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UHGPEWTZABDZCE-UHFFFAOYSA-N dipropyl decanedioate Chemical compound CCCOC(=O)CCCCCCCCC(=O)OCCC UHGPEWTZABDZCE-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- MBLYFAMRGLHMAQ-UHFFFAOYSA-N hexanedioic acid oxalic acid Chemical compound OC(=O)C(O)=O.OC(=O)CCCCC(O)=O MBLYFAMRGLHMAQ-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229950001891 iprotiazem Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical class CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-dimethylbenzene Natural products CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23517790 | 1990-09-04 | ||
| JP235177/90 | 1990-09-04 | ||
| JP235177/1990 | 1990-09-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1059468A CN1059468A (zh) | 1992-03-18 |
| CN1069193C true CN1069193C (zh) | 2001-08-08 |
Family
ID=16982211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN91108796A Expired - Lifetime CN1069193C (zh) | 1990-09-04 | 1991-09-04 | 含三环化合物的软膏的制备方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5385907A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0474126B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2526752B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100194240B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1069193C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE150304T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU656145B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2050623C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69125230T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0474126T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2099112T3 (cg-RX-API-DMAC7.html) |
| GR (1) | GR3022883T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1000006A1 (cg-RX-API-DMAC7.html) |
| HU (2) | HUT59002A (cg-RX-API-DMAC7.html) |
| IE (1) | IE913085A1 (cg-RX-API-DMAC7.html) |
| PH (1) | PH31282A (cg-RX-API-DMAC7.html) |
| PT (1) | PT98862B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2079303C1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG46547A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA916983B (cg-RX-API-DMAC7.html) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994010981A1 (fr) * | 1992-11-18 | 1994-05-26 | Fujisawa Pharmaceutical Co., Ltd. | Preparation pharmaceutique a action prolongee |
| JPH06345646A (ja) * | 1993-06-08 | 1994-12-20 | Fujisawa Pharmaceut Co Ltd | ローション剤 |
| AU735106B2 (en) * | 1994-10-26 | 2001-06-28 | Novartis Ag | Pharmaceutical compositions |
| GB2327611B (en) * | 1994-10-26 | 1999-06-02 | Novartis Ag | Macrolide compositions |
| DE19549794B4 (de) * | 1994-10-26 | 2009-07-30 | Novartis Ag | Pharmazeutische Zusammensetzungen |
| JP4155593B2 (ja) * | 1994-10-26 | 2008-09-24 | ノバルティス・アクチエンゲゼルシャフト | 医薬組成物 |
| GB2327610B (en) * | 1994-11-04 | 1999-06-02 | Novartis Ag | Macrolide compositions |
| AR004480A1 (es) * | 1995-04-06 | 1998-12-16 | Amico Derin C D | Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen |
| US5993787A (en) * | 1996-09-13 | 1999-11-30 | Johnson & Johnson Consumer Products, Inc. | Composition base for topical therapeutic and cosmetic preparations |
| AU5340298A (en) * | 1996-12-27 | 1998-07-31 | Takeda Chemical Industries Ltd. | Stabilized tricyclic compound |
| TW450810B (en) * | 1997-02-20 | 2001-08-21 | Fujisawa Pharmaceutical Co | Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases |
| GB9723669D0 (en) * | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
| RU2149635C1 (ru) * | 1998-02-27 | 2000-05-27 | Пермская государственная медицинская академия | Способ лечения аллергических дерматитов |
| TR200003108T2 (tr) * | 1998-04-27 | 2001-02-21 | Fujisawa Pharmaceutical Co., Ltd. | İlaç kompozisyonları |
| GB9817064D0 (en) * | 1998-08-05 | 1998-10-07 | Fujisawa Pharmaceutical Co | New use |
| US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
| US6300341B1 (en) | 1998-09-30 | 2001-10-09 | The Procter & Gamble Co. | 2-substituted heterocyclic sulfonamides |
| GB9826656D0 (en) | 1998-12-03 | 1999-01-27 | Novartis Ag | Organic compounds |
| AUPR529701A0 (en) * | 2001-05-28 | 2001-06-21 | Fujisawa Pharmaceutical Co., Ltd. | Pharmaceutical composition |
| RU2183113C1 (ru) * | 2001-06-28 | 2002-06-10 | Новицкий Юрий Алексеевич | Средство-гидросульфат графита и способ лечения больных с доброкачественными и злокачественными опухолями кожи (варианты) |
| WO2003004098A1 (en) | 2001-07-06 | 2003-01-16 | Sucampo Ag | Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| AR038628A1 (es) * | 2002-03-04 | 2005-01-19 | Novartis Ag | Composicion oftalmica |
| CN1674868B (zh) * | 2002-07-23 | 2010-09-29 | 诺瓦提斯公司 | 包含药物、软膏基质和增溶剂/分散剂的眼用软膏剂组合物 |
| GB0218996D0 (en) * | 2002-08-14 | 2002-09-25 | Novartis Ag | Organic compounds |
| RU2231359C1 (ru) * | 2002-12-11 | 2004-06-27 | Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М.Сеченова | Способ лечения язвенных форм ангиитов кожи |
| AU2005274574B2 (en) * | 2004-08-18 | 2011-03-17 | Ace Aps | Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists |
| CA2526419C (en) * | 2005-01-04 | 2012-09-25 | Texas United Chemical Company, Llc | Compounded hydrocarbon oil and oil base drilling fluids prepared therefrom |
| CN101119730A (zh) * | 2005-02-14 | 2008-02-06 | 大正制药株式会社 | 软膏剂 |
| JPWO2006098353A1 (ja) * | 2005-03-15 | 2008-08-28 | 協和醗酵工業株式会社 | 外用剤 |
| CN104906096A (zh) * | 2005-10-05 | 2015-09-16 | 田边三菱制药株式会社 | 皮炎治疗剂 |
| PL1992622T3 (pl) | 2006-02-21 | 2012-01-31 | Eisai R&D Man Co Ltd | Pochodna 4-(3-benzoiloaminofenylo)-6,7-dimetoksy-2-metyloaminochinazoliny |
| AU2008215411B2 (en) | 2007-02-16 | 2012-11-22 | Eisai R & D Management Co., Ltd. | Crystal, amorphous form and salt of methyl N-[3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid |
| US10265265B2 (en) | 2007-03-15 | 2019-04-23 | Drug Delivery Solutions Limited | Topical composition |
| ATE538102T1 (de) | 2007-08-17 | 2012-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung eines chinazolinderivats |
| AU2008290001B2 (en) | 2007-08-17 | 2012-08-09 | Eisai R & D Management Co., Ltd. | Novel preparation for external use |
| CN102176913B (zh) * | 2008-10-08 | 2014-08-13 | 高田制药株式会社 | 外用的他克莫司制剂 |
| JP2010132607A (ja) * | 2008-12-05 | 2010-06-17 | Taisho Pharm Ind Ltd | アトピー性皮膚炎治療用軟膏剤 |
| JP2010202546A (ja) * | 2009-03-02 | 2010-09-16 | Taisho Pharm Ind Ltd | アトピー性皮膚炎の治療用軟膏製剤 |
| US20130317053A1 (en) * | 2011-01-31 | 2013-11-28 | Osaka University | Externally-used drug for treating skin disorder and method for producing same |
| CN102885761B (zh) * | 2012-09-24 | 2015-08-05 | 浙江万晟药业有限公司 | 一种制备他克莫司软膏的方法 |
| RU2538680C2 (ru) * | 2013-03-12 | 2015-01-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Фармацевтическая композиция для лечения атопического дерматита и способ ее получения |
| RU2553600C2 (ru) * | 2013-05-16 | 2015-06-20 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Фармацевтическая композиция для лечения заболеваний кожи |
| CN104127369A (zh) * | 2014-07-02 | 2014-11-05 | 人福医药集团股份公司 | 他克莫司软膏及其制备方法 |
| ES2898849T3 (es) | 2014-10-28 | 2022-03-09 | Koushi Yamaguchi | Medicamento para mejorar el síndrome de hipertensión inducida por el embarazo |
| CN106309353A (zh) * | 2015-06-19 | 2017-01-11 | 江苏吉贝尔药业股份有限公司 | 一种治疗银屑病的软膏剂及其制备方法 |
| JP6932180B2 (ja) | 2016-04-04 | 2021-09-08 | エムシー２・セラピューティクス・リミテッドＭＣ２ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | タクロリムスを含む局所組成物 |
| CN105769752B (zh) * | 2016-04-08 | 2018-12-11 | 湖北人福成田药业有限公司 | 制备他克莫司软膏的方法及他克莫司软膏 |
| EP3542788A1 (en) | 2018-03-19 | 2019-09-25 | MC2 Therapeutics Limited | Topical composition comprising calcipotriol and betamethasone dipropionate |
| AU2019318035A1 (en) | 2018-08-10 | 2021-03-04 | Koushi Yamaguchi | Therapeutic agent for humoral immunity-related diseases in materno-fetal relationship |
| EP3930713B1 (en) * | 2018-12-04 | 2025-05-28 | Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi | Stable tacrolimus ointment formulation for topical treatment of skin conditions |
| JPWO2020129348A1 (ja) | 2018-12-18 | 2021-11-04 | 晃史 山口 | 不妊・不育症または妊娠状態を改善するための薬剤 |
| CN114767688A (zh) * | 2019-09-04 | 2022-07-22 | 武汉科福新药有限责任公司 | 透皮促渗组合物及其在噻吗洛尔制剂中的应用 |
| EP4114357B1 (en) | 2020-03-02 | 2025-10-01 | Shanghai Aucta Pharmaceuticals Co., Ltd. | Topical formulations containing mtor inhibitors |
| CN112022798B (zh) * | 2020-08-11 | 2022-04-29 | 四川大学华西医院 | 一种速效他克莫司软膏、制备方法及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH26083A (en) * | 1987-11-09 | 1992-02-06 | Sandoz Ltd | 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof |
| KR0159766B1 (ko) * | 1989-10-16 | 1998-12-01 | 후지사와 토모키치로 | 양모제 조성물 |
| US5061700A (en) * | 1989-11-16 | 1991-10-29 | Gordon Jay Dow | Glyceryl acetate ointment vehicles |
-
1991
- 1991-08-30 AT AT91114598T patent/ATE150304T1/de not_active IP Right Cessation
- 1991-08-30 DE DE69125230T patent/DE69125230T2/de not_active Expired - Lifetime
- 1991-08-30 SG SG1996005797A patent/SG46547A1/en unknown
- 1991-08-30 AU AU83515/91A patent/AU656145B2/en not_active Expired
- 1991-08-30 ES ES91114598T patent/ES2099112T3/es not_active Expired - Lifetime
- 1991-08-30 DK DK91114598.5T patent/DK0474126T3/da active
- 1991-08-30 EP EP91114598A patent/EP0474126B1/en not_active Expired - Lifetime
- 1991-09-02 KR KR1019910015225A patent/KR100194240B1/ko not_active Expired - Lifetime
- 1991-09-02 IE IE308591A patent/IE913085A1/en not_active IP Right Cessation
- 1991-09-03 PH PH43041A patent/PH31282A/en unknown
- 1991-09-03 HU HU912846A patent/HUT59002A/hu unknown
- 1991-09-03 RU SU5001707/14A patent/RU2079303C1/ru active Protection Beyond IP Right Term
- 1991-09-03 ZA ZA916983A patent/ZA916983B/xx unknown
- 1991-09-04 PT PT98862A patent/PT98862B/pt not_active IP Right Cessation
- 1991-09-04 JP JP3224418A patent/JP2526752B2/ja not_active Expired - Lifetime
- 1991-09-04 CN CN91108796A patent/CN1069193C/zh not_active Expired - Lifetime
- 1991-09-04 CA CA002050623A patent/CA2050623C/en not_active Expired - Lifetime
-
1993
- 1993-05-17 US US08/062,330 patent/US5385907A/en not_active Expired - Lifetime
-
1995
- 1995-06-22 HU HU95P/P00363P patent/HU211470A9/hu unknown
-
1997
- 1997-03-21 GR GR970400563T patent/GR3022883T3/el unknown
- 1997-07-10 HK HK97101531A patent/HK1000006A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2526752B2 (ja) | 1996-08-21 |
| ATE150304T1 (de) | 1997-04-15 |
| DK0474126T3 (cg-RX-API-DMAC7.html) | 1997-04-07 |
| PT98862A (pt) | 1992-08-31 |
| CA2050623C (en) | 2002-02-05 |
| RU2079303C1 (ru) | 1997-05-20 |
| AU656145B2 (en) | 1995-01-27 |
| ZA916983B (en) | 1992-05-27 |
| IE913085A1 (en) | 1992-03-11 |
| HUT59002A (en) | 1992-04-28 |
| DE69125230D1 (de) | 1997-04-24 |
| JPH0517481A (ja) | 1993-01-26 |
| PT98862B (pt) | 1999-02-26 |
| KR100194240B1 (ko) | 1999-06-15 |
| DE69125230T2 (de) | 1997-07-10 |
| CA2050623A1 (en) | 1992-03-05 |
| GR3022883T3 (en) | 1997-06-30 |
| CN1059468A (zh) | 1992-03-18 |
| KR920005987A (ko) | 1992-04-27 |
| PH31282A (en) | 1998-07-06 |
| SG46547A1 (en) | 1998-02-20 |
| EP0474126B1 (en) | 1997-03-19 |
| HU211470A9 (en) | 1995-11-28 |
| HK1000006A1 (en) | 1997-10-03 |
| EP0474126A1 (en) | 1992-03-11 |
| ES2099112T3 (es) | 1997-05-16 |
| US5385907A (en) | 1995-01-31 |
| AU8351591A (en) | 1992-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1069193C (zh) | 含三环化合物的软膏的制备方法 | |
| KR100354607B1 (ko) | 로션제 | |
| HK1000006B (en) | Ointments containing tricyclic compound | |
| HK1038884B (zh) | 药物组合物 | |
| JPWO1994028894A1 (ja) | ローション剤 | |
| CN86106153A (zh) | 新型半透明油包水乳液 | |
| CN1048322A (zh) | 表面凝胶配方和粉刺的治疗方法 | |
| HU226163B1 (en) | Pharmaceutical compositions containing fk-506 and derivatives thereof | |
| CN1213767C (zh) | 含有子囊霉素的局部用组合物 | |
| CN1069194C (zh) | 药物组合物的制备方法 | |
| CA2495345A1 (en) | Topical anhydrous and ethanol-free ascomycin compositions | |
| EP0175609B1 (fr) | Composition anesthésique percutanée pour usage topique et procédé d'application | |
| CN1112918A (zh) | 氟化维生素d3衍生物 | |
| CN1679962A (zh) | 药物组合物 | |
| CN1103580A (zh) | 大环内酯化合物的新用途 | |
| US5215995A (en) | Hair revitalizing agent | |
| CN1173692C (zh) | 化妆品组合物和降低皮肤老化过程的方法 | |
| TW202142237A (zh) | 包含2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)-1h-吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4,4-二甲基戊-2-烯腈之局部醫藥組成物 | |
| MXPA99007451A (en) | Pharmaceutical composition | |
| HK1029943B (en) | A cosmetic composition and a method for reducing the ageing processes of skin | |
| CN1179710A (zh) | 透过皮肤吸收的制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
| OR01 | Other related matters | ||
| ASS | Succession or assignment of patent right |
Owner name: ASTELLAS PHARMA INC. Free format text: FORMER OWNER: FUJISAWA PHARMACEUTICAL CO., LTD. Effective date: 20060407 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20060407 Address after: Tokyo, Japan Patentee after: Yamanouchi Pharma Co., Ltd. Address before: Osaka City, Osaka of Japan Patentee before: Fujisawa Pharmaceutical Co., Ltd. |
|
| C17 | Cessation of patent right | ||
| CX01 | Expiry of patent term |
Expiration termination date: 20110904 Granted publication date: 20010808 |